6533b839fe1ef96bd12a5b6f
RESEARCH PRODUCT
Update on topical carbonic anhydrase inhibitors
Norbert PfeifferUlrike Herkelsubject
Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugdescription
Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for the long-term outcome for human glaucoma remains to be shown. Side effects are mostly local. A more physiologic pH of brinzolamide appears to be advantageous.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2001-04-01 | Current Opinion in Ophthalmology |